Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Spero Therapeutics Inc SPRO

Healthcare Biotechnology
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with unmet need. Its lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease... see more

Recent & Breaking News (NDAQ:SPRO)

Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review

GlobeNewswire May 9, 2019

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 1, 2019

Spero Therapeutics Receives FDA Fast Track Designation for SPR994 for the treatment of Complicated Urinary Tract infections and Acute Pyelonephritis

GlobeNewswire March 29, 2019

Spero Announces Appointment of Cynthia Smith to its Board of Directors

GlobeNewswire March 19, 2019

Spero Therapeutics Announces Fourth Quarter and Full Year 2018 Operating Results and Provides Pipeline Review

Business Wire March 14, 2019

Spero Therapeutics to Present at March Investor Conferences

GlobeNewswire March 1, 2019

Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR720

GlobeNewswire February 26, 2019

Spero Therapeutics Announces FDA Acceptance of IND Application for SPR994

GlobeNewswire February 4, 2019

Spero Therapeutics Announces Initiation of SPR720 Phase 1 Clinical Trial

GlobeNewswire January 29, 2019

Spero Therapeutics Signs License Agreement with Everest Medicines to Develop, Manufacture and Commercialize SPR206 in Asia, with Option for SPR741 Rights, and Initiates SPR206 Phase 1 Clinical Trial

GlobeNewswire January 7, 2019

Spero Therapeutics Announces Positive Feedback from FDA Pre-Phase 3 Meeting for Oral SPR994 and Submission of IND for SPR994 in cUTI

GlobeNewswire January 7, 2019

New Research: Key Drivers of Growth for Mersana Therapeutics, Maiden, Payment Data, CareDx, Natera, and Spero Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire November 28, 2018

Spero Therapeutics Announces Third Quarter 2018 Financial Results and Pipeline Overview

GlobeNewswire November 8, 2018

Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial

GlobeNewswire November 5, 2018

New Research: Key Drivers of Growth for IDT, Live Nation Entertainment, BioDelivery Sciences International, Spero Therapeutics, Aimmune Therapeutics, and Cars — Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire October 17, 2018

Spero Therapeutics Receives QIDP Designation from the U.S. FDA for the Development of SPR206

GlobeNewswire October 11, 2018

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2018

PR Newswire October 3, 2018

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs

Benzinga.com  September 30, 2018

Spero Announces Positive SPR994 Phase 1 SAD/MAD Final Results

GlobeNewswire September 27, 2018

Spero Therapeutics Announces Presentations at IDWeek 2018

GlobeNewswire September 25, 2018